← Eichor
Study identifier: NCT05872685 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)

Condition: Adenocarcinoma of the Stomach · Adenocarcinoma of Esophagogastric Junction · Proficient Mismatch Repair  ·  Sponsor: Yu jiren

PhasePhase 2
Planned participants314
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This phase II study is a prospective, multi-center, double-blinded, and randomized trial to compare the efficacy and safety of perioperative SOX plus serplulimab with SOX plus placebo for locally advanced gastric adenocarcinoma with proficient mismatch repair

This description comes directly from the study's public registry record.

Talk to the study team

Jiren Yu  ·  +86-0571-87236147  ·  yujr0909@zju.edu.cn

Always discuss trial participation with your own doctor first.

Locations (5)

The First Affiliated Hospital, College of Medicine, Zhejiang UniversityHangzhou, Zhejiang, ChinaRecruiting
The Second Affiliated Hospital, College of Medicine, Zhejiang UniversityHangzhou, Zhejiang, ChinaNot Yet Recruiting
Lishui Central HospitalLishui, Zhejiang, ChinaNot Yet Recruiting
Ningbo Medical Center LiHuiLi HospitalNingbo, Zhejiang, ChinaNot Yet Recruiting
Taizhou HospitalTaizhou, Zhejiang, ChinaNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05872685